| JOURNAL OF MOLECULAR BIOLOGY | 卷:431 |
| β-Lactamases and β-Lactamase Inhibitors in the 21st Century | |
| Review | |
| Tooke, Catherine L.1  Hinchliffe, Philip1  Bragginton, Eilis C.1  Colenso, Charlotte K.1  Hirvonen, Viivi H. A.1  Takebayashi, Yuiko1  Spencer, James1  | |
| [1] Univ Bristol, Sch Cellular & Mol Med, Biomed Sci Bldg, Bristol BS8 1TD, Avon, England | |
| 关键词: beta-lactam; antimicrobial resistance; carbapenemase; enzyme mechanism; | |
| DOI : 10.1016/j.jmb.2019.04.002 | |
| 来源: Elsevier | |
PDF
|
|
【 摘 要 】
The beta-lactams retain a central place in the antibacterial armamentarium. In Gram-negative bacteria, beta-lactamase enzymes that hydrolyze the amide bond of the four-membered beta-lactam ring are the primary resistance mechanism, with multiple enzymes disseminating on mobile genetic elements across opportunistic pathogens such as Enterobacteriaceae (e.g., Escherichia coli) and non-fermenting organisms (e.g., Pseudomonas aeruginosa). beta-Lactamases divide into four classes; the active-site serine beta-lactamases (classes A, C and D) and the zinc-dependent or metallo-beta-lactamases (MBLs; class B). Here we review recent advances in mechanistic understanding of each class, focusing upon how growing numbers of crystal structures, in particular for beta-lactam complexes, and methods such as neutron diffraction and molecular simulations, have improved understanding of the biochemistry of beta-lactam breakdown. A second focus is beta-lactamase interactions with carbapenems, as carbapenem-resistant bacteria are of grave clinical concern and carbapenem-hydrolyzing enzymes such as KPC (class A) NDM (class B) and OXA-48 (class D) are proliferating worldwide. An overview is provided of the changing landscape of beta-lactamase inhibitors, exemplified by the introduction to the clinic of combinations of beta-lactams with diazabicyclooctanone and cyclic boronate serine beta-lactamase inhibitors, and of progress and strategies toward clinically useful MBL inhibitors. Despite the long history of beta-lactamase research, we contend that issues including continuing unresolved questions around mechanism; opportunities afforded by new technologies such as serial femtosecond crystallography; the need for new inhibitors, particularly for MBLs; the likely impact of new beta-lactam:inhibitor combinations and the continuing clinical importance of beta-lactams mean that this remains a rewarding research area. (C) 2019 The Authors. Published by Elsevier Ltd.
【 授权许可】
Free
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 10_1016_j_jmb_2019_04_002.pdf | 4156KB |
PDF